Table 1.

Effect of sunitinib, sorafenib, and rMVA–CEA–TRICOM vaccine on the phenotype of tumor-infiltrating MDSCs and TAMs in the MC38-CEA tumor model

Control % (±SEM)Sun % (±SEM)Sor % (±SEM)Vac % (±SEM)Sun + vac % (±SEM)Sor + vac % (±SEM)
MDSCsTotal MDSCsa6.3 (1.1)20.3 (2.5)b21.2 (1.1)b8.4 (1.5)22.7 (3.0)b22.1 (4.9)b
FAS-Lc18.8 (3.2)35.2 (5.5)d41.7 (3.3)b19.9 (3.6)39.6 (2.3)b33.5 (3.1)d
CXCL-9c33.1 (5.6)59.3 (9.6)d65.2 (8.8)d40.0 (2.2)59.9 (2.6)d57.0 (5.2)d
CD31c1.5 (0.2)6.8 (3.1)12.2 (5.1)2.3 (0.6)8.5 (0.7)8.1 (2.6)
CD105c38.3 (4.0)60.2 (10.6)65.9 (12.6)40.3 (2.0)71.1 (2.4)d54.6 (3.7)
TAMsTotal TAMse65.0 (4.2)54.7 (5.2)44.5 (6.6)d62.5 (1.7)42.9 (4.4)d44.1 (1.1)d
FAS-Lf18.0 (2.2)45.7 (8.9)d55.3 (14.1)d21.3 (3.7)58.6 (3.9)d47.2 (4.1)d
CXCL-9f0.5 (0.2)4.3 (2.7)14.3 (2.7)0.8 (0.3)5.9 (0.8)11.0 (2.2)b
CD31f2.9 (0.8)11.1 (2.7)14.9 (3.8)d3.5 (0.8)14.5 (0.7)d13.1 (3.1)d
CD105f33.4 (3.7)59.6 (14.8)70.0 (13.4)d34.9 (3.7)74.5 (2.0)d58.0 (5.9)

NOTE: Flow-cytometric analysis of single-cell suspensions of 21-day-old MC38-CEA subcutaneous tumors from CEA-tg C57BL/6 mice (n = 3/group).

Abbreviations: Control, no treatment; Sor, sorafenib on day 7; Sun, sunitinib on day 7; Vac, rMVA–CEA–TRICOM vaccine on day 14; Sor+vac, sorafenib on day 7 followed by rMVA–CEA–TRICOM vaccine on day 14; Sun + vac, sunitinib on day 7 followed by rMVA–CEA–TRICOM vaccine on day 14.

Bold values indicate statistically significant difference compared with control based on the one-way ANOVA test versus the control group.

  • aThe percentage of MDSCs identified as CD45+ intratumoral cells CD11b+Gr1+.

  • bP < 0.01.

  • cFrequency of MDSCs positive for the activation marker.

  • dP < 0.05.

  • eThe percentage of TAMs identified as CD45+ intratumoral cells CD11b+Gr1.

  • fFrequency of TAMs positive for the activation marker.